Equities

Oxford Biomedica PLC

Oxford Biomedica PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)279.10
  • Today's Change2.60 / 0.94%
  • Shares traded75.50k
  • 1 Year change-35.69%
  • Beta1.4169
Data delayed at least 20 minutes, as of May 01 2024 08:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy1
Outperform4
Hold4
Underperform0
Sell0

Share price forecast in GBX

The 8 analysts offering 12 month price targets for Oxford BioMedica plc have a median target of 392.50, with a high estimate of 740.00 and a low estimate of 180.00. The median estimate represents a 41.95% increase from the last price of 276.50.
High167.6%740.00
Med42.0%392.50
Low-34.9%180.00

Earnings history & estimates in GBX

Oxford BioMedica plc reported annual 2023 losses of -60.28 per share on Apr 29, 2024.
Average growth rate+9.53%
More ▼

Revenue history & estimates in GBP

Oxford Biomedica plc had revenues for the full year 2023 of 89.54m. This was 36.04% below the prior year's results.
Average growth rate+15.43%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.